Bioyitech Showcases at Hangzhou's "New Nutrition Conference," Discussing the Future Transformation of the Probiotic Industry
From June 5th to 6th, 2025, the 13th New Nutrition Conference was grandly held at the Hangzhou Grand Hotel. The New Nutrition Conference focuses on the innovation trends in the big health industry and is a grand event in the field of functional raw materials. Bioyitech, a leading domestic probiotic enterprise, was invited to attend and won the "Best-Selling Product Award" in the intestinal health category. At this New Nutrition Conference, Li Jiadong, Co-founder and General Manager of Bioyitech, attended the roundtable forum and discussed the "Future Transformation of the Probiotic Industry" with industry experts; in addition, Zheng Chao, Chief Physician of Bioyitech's clinical project and Director of the Department of Endocrinology at the Second Affiliated Hospital of Zhejiang University School of Medicine, delivered a keynote speech, sharing the cutting-edge applications of Probiotics in metabolic disease management.
Roundtable Forum: Foresight into the Transformation Direction of the Probiotic Industry
In the roundtable discussion on "Future Transformation of the Probiotic Industry," Li Jiadong, Co-founder and General Manager of Bioyitech, analyzed from multiple dimensions, including technology research and development, market trends, and policy guidance. He pointed out: "With the improvement of consumers' health awareness and the accumulation of clinical evidence, the probiotic industry is upgrading from traditional 'intestinal health' to 'precise targeted function.' In the next 5 years, strain customization, evidence-based medical research, and cross-disciplinary cooperation will become the key to industry breakthroughs." Li Jiadong also emphasized Bioyitech's advantages in strain screening and clinical transformation, stating that the company will accelerate the promotion of "probiotic +" in the field of chronic disease management.
Keynote Speech: Probiotics Assist in the Prevention and Treatment of Metabolic Diseases
Professor Zheng Chao, Director of the Department of Endocrinology at the Second Affiliated Hospital of Zhejiang University, delivered a speech titled "Treating Chronic Diseases and Preventing Unseen Diseases: Probiotics Assist in Metabolic Disease Management" at the main forum of the conference. Combining clinical data and cases, he systematically explained the intervention potential of probiotics include Bifidobacterium animalis subsp.lactis F1-7, Lacticaseibacillus paracasei J5, Lactiplantibacillus plantarum F3-2,Bifidobacterium animalis subsp.lactis BA-C53 on metabolic diseases such as diabetes and obesity. Director Zheng Chao said: "Intestinal flora regulation has become a new target for metabolic disease management. Our clinical trials show that specific Probiotic Strains can significantly improve insulin sensitivity and inflammatory indicators, providing new ideas for 'nutritional therapy.'" This research result sparked heated discussions among the experts present, further solidifying the scientific value of probiotics in the field of medical health.
Bioyitech Wins the "Best-Selling Product Award" in the Intestinal Health Category, Leading Probiotic Industry Innovation with Scientific Research Strength
As a national high-tech enterprise in the field of functional probiotic research and development, Bioyitech has always adhered to the concept of "scientific research driving health," and is committed to transforming cutting-edge microbial research results into effective health solutions. At the recently concluded 2025 New Nutrition Conference, the company's star product, "Jiang Xiaoyi Instant Lactic Acid Bacteria," won the "Best-Selling Product Award" in the intestinal health category for its excellent product strength and clinical value, once again demonstrating the company's leading position in the field of probiotic innovation.
This award is another important milestone for Bioyitech's continuous deep cultivation in the field of functional probiotics. In the future, the company will continue to use technological innovation as the engine, deepen strategic cooperation with medical institutions, bring more health products with clinical value to consumers, and contribute to the realization of the "Healthy China 2030" strategic goal.